There is an epidemic of turbo cancers, one such study supports this statement as provide with a link in prior posting. Many other publications made available further supports this concerning new trend. Impeded Limited has at large concentrated on breast cancer. It is unfortunate that the turbo cancer epidemic has also seen an alarming increase of breast cancer.
For new investors considering an investment in this company (Impedimed limited) I intend to keep this thread entitled “Turbo cancers but no sales” as an accumulative ongoing thread. I believe highlighting issues in a fair and balanced manner, both good and of course, opportunities for improvement. I aim to remove any looking through rose coloured glass commentary by being fair and balanced.
Resulting from this concerning epidemic of turbo cancers, supported by first to market Sozo device and the roll out of medical insurance guidelines supporting best practice use of control for the prevention and control of Lymphedema, why have Sozo sales lacked in meaningful quantity. Maybe a good question to ask chatGP but equally a reasonable question to be asked to current. BoD.
To new investors, does this company present with a good entry share price opportunity, will this current BoD be able to magnify their quarterly Sozo device sales targets and is it too early and/or too late to invest in this company. All reasonable questions that an investor would what to know, which I aim to try and breakdown day by day and week by week following the commencement of this thread.
to those who have taken their option to place me on ignore I apply a very sincere thank you for allowing me a blank canvas to be able to articulate fair imbalance reporting without being sabotage.
there is a better way
ChatGP
Add to My Watchlist
What is My Watchlist?
